FR09C0041I2 - - Google Patents

Info

Publication number
FR09C0041I2
FR09C0041I2 FR09C0041C FR09C0041C FR09C0041I2 FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2 FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 C FR09C0041 C FR 09C0041C FR 09C0041 I2 FR09C0041 I2 FR 09C0041I2
Authority
FR
France
Prior art keywords
pain
inflammatory
chronic
analgesics
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0041C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanol Schwarz GmbH
UCB Pharma GmbH
Original Assignee
Sanol Schwarz GmbH
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Schwarz GmbH, Schwarz Pharma AG filed Critical Sanol Schwarz GmbH
Publication of FR09C0041I1 publication Critical patent/FR09C0041I1/fr
Application granted granted Critical
Publication of FR09C0041I2 publication Critical patent/FR09C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
FR09C0041C 2001-03-20 2009-09-07 Active FR09C0041I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01106891A EP1243262B1 (fr) 2001-03-20 2001-03-20 Nouvelle utilisation d'un composé peptidique pour le traitement de la douleur inflammatoire non-neuropathique
EP02727437A EP1373300B1 (fr) 2001-03-20 2002-03-19 Nouvelle utilisation d'une classe de composes peptidiques pour le traitement de douleurs inflammatoires non neuropathiques
PCT/EP2002/003034 WO2002074784A2 (fr) 2001-03-20 2002-03-19 Nouvelle utilisation d'une classe de composes peptidiques pour le traitement de douleurs inflammatoires non neuropathiques

Publications (2)

Publication Number Publication Date
FR09C0041I1 FR09C0041I1 (fr) 2009-10-30
FR09C0041I2 true FR09C0041I2 (fr) 2010-01-22

Family

ID=8176844

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0041C Active FR09C0041I2 (fr) 2001-03-20 2009-09-07

Country Status (31)

Country Link
US (3) US6803481B2 (fr)
EP (2) EP1243262B1 (fr)
JP (1) JP4955906B2 (fr)
KR (1) KR100773100B1 (fr)
CN (2) CN101332292B (fr)
AT (2) ATE327744T1 (fr)
AU (1) AU2002257681C1 (fr)
BR (1) BR0205823A (fr)
CA (1) CA2419397C (fr)
CY (3) CY1105533T1 (fr)
CZ (1) CZ20032763A3 (fr)
DE (3) DE60120104T2 (fr)
DK (2) DK1243262T3 (fr)
EA (1) EA007532B1 (fr)
ES (2) ES2262567T3 (fr)
FR (1) FR09C0041I2 (fr)
HK (1) HK1058368A1 (fr)
HU (1) HUP0303600A3 (fr)
IL (2) IL154087A0 (fr)
LU (1) LU91590I2 (fr)
MX (1) MXPA03008467A (fr)
NL (1) NL300399I1 (fr)
NO (1) NO20033629L (fr)
NZ (1) NZ523865A (fr)
PL (1) PL216213B1 (fr)
PT (2) PT1243262E (fr)
SI (2) SI1373300T1 (fr)
SK (1) SK287539B6 (fr)
UA (1) UA82645C2 (fr)
WO (1) WO2002074784A2 (fr)
ZA (1) ZA200300858B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486206B1 (fr) * 2000-08-25 2007-10-17 Research Corporation Technologies, Inc Utilisations d'acides aminés anticonvulsifs pour traiter les désordres bipolaires
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
KR20060111524A (ko) * 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (fr) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
MXPA06011937A (es) * 2004-04-16 2007-01-26 Sanol Arznei Schwarz Gmbh Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico.
CN100562312C (zh) * 2004-05-18 2009-11-25 舒沃茨药物股份公司 肽化合物用于治疗运动障碍的新用途
EP1604654A1 (fr) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604655A1 (fr) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
MX2007002269A (es) * 2004-08-27 2007-06-15 Sanol Arznei Schwarz Gmbh Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
EP1642889A1 (fr) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
KR20070096058A (ko) 2005-01-28 2007-10-01 쉬바르츠파르마에이지 정신분열증의 부가 요법용 ｓｐｍ 927
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (fr) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
KR20090018863A (ko) * 2006-06-08 2009-02-23 쉬바르츠파르마에이지 통증성 의학적 상태를 위한 치료제 조합
EP1873527A1 (fr) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
EP1920780A1 (fr) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
KR20150003925A (ko) 2006-06-15 2015-01-09 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
WO2011037833A2 (fr) 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Nouveaux dérivés à substitution n-benzylamide d'acide 2-(acylamido)acétique et d'acides 2-(acylamido)propioniques : agents neurologiques puissants
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (fr) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (fr) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5278729A (en) * 1992-04-10 1994-01-11 Magnavox Electronic Systems Company Compact rotatable electrical device
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
US5902791A (en) * 1994-01-22 1999-05-11 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) * 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
HUT77282A (hu) 1994-10-05 1998-03-30 Darwin Discovery Limited Peptidvegyületek és gyógyászati alkalmazásuk metalloproteáz inhibitorokként
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (fr) * 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Inhibiteurs de la substance p associes a des inhibiteurs nmda pour traiter la douleur
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
CN1278251A (zh) 1997-10-31 2000-12-27 Basf公司 新的带酰胺侧链的羧酸衍生物及其制备方法和作为内皮素受体拮抗剂的用途
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IL143935A (en) 1999-09-03 2005-08-31 Actelion Pharmaceuticals Ltd Bis-sulfonamides
SE0001373D0 (sv) * 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
US20020052418A1 (en) 2000-08-17 2002-05-02 Mitchell Shirvan Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
EP1486206B1 (fr) * 2000-08-25 2007-10-17 Research Corporation Technologies, Inc Utilisations d'acides aminés anticonvulsifs pour traiter les désordres bipolaires
DE60134337D1 (de) 2000-11-21 2008-07-17 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
NZ527276A (en) 2001-03-27 2004-11-26 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
BR0209155A (pt) 2001-04-26 2004-10-05 Bristol Myers Squibb Co Tablete farmacêutico tendo um teor de api elevado
ITMI20011308A1 (it) * 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7384934B2 (en) 2002-08-05 2008-06-10 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
EP1575919A1 (fr) 2002-11-11 2005-09-21 Bayer HealthCare AG Derives de phenyl- ou heteroarylamino-alcanes comme antagonistes du recepteur ip
WO2004046178A2 (fr) 2002-11-18 2004-06-03 Stewart John M Peptide paralytique utilisable dans un traitement neuromusculaire
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
ATE353633T1 (de) 2002-12-19 2007-03-15 Pharmacia Corp Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
CA2514574A1 (fr) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methodes destinees a traiter les troubles du tractus gastro-intestinal au moyen de modulateurs du canal sodique
EP1589959A2 (fr) 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methodes destinees a traiter les troubles du tractus urinaire inferieur au moyen de modulateurs du canal sodique
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
KR20060111524A (ko) 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1537862A1 (fr) 2003-12-02 2005-06-08 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la douleur neuropathique centrale
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (fr) 2003-12-05 2005-06-15 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la status epilepticus et etats connexes
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (fr) 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
MXPA06011937A (es) 2004-04-16 2007-01-26 Sanol Arznei Schwarz Gmbh Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico.
EP1604654A1 (fr) 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
EP1604655A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
MX2007002269A (es) 2004-08-27 2007-06-15 Sanol Arznei Schwarz Gmbh Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
EP1642889A1 (fr) 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (fr) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 pour la thérapie adjuvante de la schizophrenie
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie

Also Published As

Publication number Publication date
EP1243262A1 (fr) 2002-09-25
NO20033629D0 (no) 2003-08-15
ATE327744T1 (de) 2006-06-15
LU91590I2 (fr) 2009-10-05
JP2004524340A (ja) 2004-08-12
PL216213B1 (pl) 2014-03-31
UA82645C2 (uk) 2008-05-12
HUP0303600A2 (hu) 2004-03-01
SI21170A (sl) 2003-10-31
CN101332292B (zh) 2012-06-20
ES2262567T3 (es) 2006-12-01
IL154087A (en) 2010-05-17
EP1243262B1 (fr) 2006-05-31
CN100415225C (zh) 2008-09-03
EA200300932A1 (ru) 2004-04-29
ES2326627T3 (es) 2009-10-16
DK1243262T3 (da) 2006-10-02
CY1109308T1 (el) 2012-01-25
ATE431833T1 (de) 2009-06-15
CN1498103A (zh) 2004-05-19
HK1058368A1 (en) 2004-05-14
PT1373300E (pt) 2009-07-22
NZ523865A (en) 2004-12-24
BR0205823A (pt) 2003-10-21
KR100773100B1 (ko) 2007-11-02
CA2419397C (fr) 2009-09-15
US6803481B2 (en) 2004-10-12
NL300399I1 (en) 2009-10-01
CY1105533T1 (el) 2010-07-28
CY2009013I1 (el) 2012-01-25
CN101332292A (zh) 2008-12-31
US20050085423A1 (en) 2005-04-21
EA007532B1 (ru) 2006-10-27
PT1243262E (pt) 2006-10-31
HUP0303600A3 (en) 2011-11-28
SI1373300T1 (sl) 2009-10-31
WO2002074784A3 (fr) 2002-11-21
US20070054962A1 (en) 2007-03-08
DE60232407D1 (de) 2009-07-02
KR20040004369A (ko) 2004-01-13
DE60120104T2 (de) 2006-09-21
MXPA03008467A (es) 2003-12-08
US20030171300A1 (en) 2003-09-11
PL362985A1 (en) 2004-11-15
DE60120104D1 (de) 2006-07-06
IL154087A0 (en) 2003-07-31
DE122009000053I1 (de) 2010-05-27
US8053476B2 (en) 2011-11-08
CA2419397A1 (fr) 2002-09-26
CZ20032763A3 (cs) 2004-01-14
EP1373300B1 (fr) 2009-05-20
JP4955906B2 (ja) 2012-06-20
AU2002257681C1 (en) 2008-02-21
EP1373300A2 (fr) 2004-01-02
AU2002257681B2 (en) 2007-06-07
AU2002257681A2 (en) 2002-10-03
CY2009013I2 (el) 2012-01-25
DK1373300T3 (da) 2009-08-31
ZA200300858B (en) 2003-07-09
SK12832003A3 (sk) 2004-02-03
FR09C0041I1 (fr) 2009-10-30
NO20033629L (no) 2003-08-15
WO2002074784A2 (fr) 2002-09-26
SK287539B6 (sk) 2011-01-04

Similar Documents

Publication Publication Date Title
FR09C0041I2 (fr)
CA2199664A1 (fr) Nouvelle prodrogue pour le traitement des tumeurs et des affections inflammatoires
MXPA04001891A (es) Inhibidores policiclicos de guanina fosfodiesterasa v.
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
BR9911137A (pt) Processo para tratamento de correntes de fluido
CY1112555T1 (el) Διεργασια χημικης συζευξης με ενα παραγωγο φαινυλ βορονικου οξεος
CA2461567A1 (fr) Composes substitues de sulfamide benzene de pyrazolyl destines au traitement des inflammations
GB9925016D0 (en) Binding surface
WO2003093242A3 (fr) Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
DK1181286T3 (da) 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylsyre hydroxamider
GB2360787B (en) An immobilised mircobial consortium for the treatment of phenolic waste-water from petroleum refineries
CA2485298A1 (fr) Composes substitues de pyrazolyl utilises dans le traitement des inflammations
WO2002070457A8 (fr) Inhibiteur de la capture de la monoamine
DE602004032548D1 (de) Derivate von hydroxamsäure als metalloproteinaseinhibitoren
ITRM20000357A0 (it) Processo per il trattamento di reflui di frantoi oleari.
FR2802196B3 (fr) Enceinte reactionnelle pour la denitrification des eaux usees
ITMI20022052A1 (it) Composti metallocenici stabilizzati di metalli di transizione del gruppo 4 e processo per la loro preparazione.
FR2818292B1 (fr) Chambre de reaction metallique anti-corrosion de procede cvd ou rtp
EP1385510A4 (fr) Composition de prodigiosine pour le traitement de l'arthrite rhumatismale
FR2880427B1 (fr) Procede pour le dosage de l'acidite des hydrocarbures